Publications of Stefanie Heynck
All genres
Journal Article (13)
2015
Journal Article
526 (7575), pp. 700 - 704 (2015)
Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature 2012
Journal Article
44 (10), pp. 1104- - 11xx (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics
Journal Article
109 (42), pp. 17034 - 17039 (2012)
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America 2011
Journal Article
1 (1), pp. 78 - 89 (2011)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery
Journal Article
17 (23), pp. 7394 - 7401 (2011)
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research
Journal Article
19 (1), pp. 429 - 439 (2011)
Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. Bioorganic and Medicinal Chemistry 2010
Journal Article
53 (7), pp. 2892 - 2901 (2010)
Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. Journal of Medicinal Chemistry
Journal Article
5 (1), p. e8919 - e8919 (2010)
Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. PLoS ONE
Journal Article
70 (3), pp. 868 - 874 (2010)
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research
Journal Article
2 (62), p. 62ra93 - 62ra93 (2010)
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine 2009
Journal Article
106, pp. 18351 - 18356 (2009)
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America
Journal Article
119 (6), pp. 1727 - 1740 (2009)
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. Journal of Clinical Investigation
Journal Article
69 (8), pp. 3256 - 3261 (2009)
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research